CYTHW
Income statement / Annual
Last year (2023), Cyclo Therapeutics, Inc.'s total revenue was $1.08 M,
a decrease of 21.76% from the previous year.
In 2023, Cyclo Therapeutics, Inc.'s net income was -$20.06 M.
See Cyclo Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.08 M |
$1.38 M |
$1.59 M |
$903,376.00 |
$1.01 M |
$1.01 M |
$1.24 M |
$1.50 M |
$950,455.00 |
$1.57 M |
| Cost of Revenue |
$98,458.00
|
$138,929.00
|
$156,080.00
|
$66,398.00
|
$75,493.00
|
$105,026.00
|
$132,918.00
|
$198,429.00
|
$124,425.00
|
$272,641.00
|
| Gross Profit |
$977,947.00
|
$1.24 M
|
$1.43 M
|
$836,978.00
|
$931,705.00
|
$906,451.00
|
$1.10 M
|
$1.30 M
|
$826,030.00
|
$1.29 M
|
| Gross Profit Ratio |
0.91
|
0.9
|
0.9
|
0.93
|
0.93
|
0.9
|
0.89
|
0.87
|
0.87
|
0.83
|
| Research and Development Expenses |
$14.18 M
|
$9.00 M
|
$9.15 M
|
$6.10 M
|
$4.87 M
|
$2.71 M
|
$2.29 M
|
$1.86 M
|
$658,505.00
|
$94,133.00
|
| General & Administrative Expenses |
$5.66 M
|
$7.81 M
|
$6.50 M
|
$3.68 M
|
$3.43 M
|
$2.43 M
|
$2.62 M
|
$2.64 M
|
$2.22 M
|
$1.53 M
|
| Selling & Marketing Expenses |
$3,902.00
|
$13,060.00
|
$18,336.00
|
$5,006.00
|
$5,885.00
|
$5,643.00
|
$7,847.00
|
$7,159.00
|
$7,569.00
|
$10,899.00
|
| Selling, General & Administrative Expenses |
$6.83 M
|
$7.82 M
|
$6.52 M
|
$3.68 M
|
$3.44 M
|
$2.44 M
|
$2.63 M
|
$2.65 M
|
$2.23 M
|
$1.55 M
|
| Other Expenses |
$0.00
|
$30,500.00
|
$27,535.00
|
$19,951.00
|
$13,976.00
|
$13,945.00
|
$19,771.00
|
$130,953.00
|
$202,015.00
|
$217,518.00
|
| Operating Expenses |
$21.04 M
|
$16.85 M
|
$15.70 M
|
$9.80 M
|
$8.32 M
|
$5.16 M
|
$4.95 M
|
$4.65 M
|
$3.09 M
|
$1.86 M
|
| Cost And Expenses |
$21.13 M
|
$16.99 M
|
$15.85 M
|
$9.86 M
|
$8.40 M
|
$5.27 M
|
$5.08 M
|
$4.85 M
|
$3.22 M
|
$2.13 M
|
| Interest Income |
$0.00
|
$12,474.00
|
$3,405.00
|
$19,802.00
|
$12,027.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$28,603.00
|
$31,290.00
|
$33,673.00
|
| Depreciation & Amortization |
$19,276.00
|
$19,481.00
|
$16,827.00
|
$12,763.00
|
$5,681.00
|
$10,124.00
|
$9,271.00
|
$107,096.00
|
$169,030.00
|
$152,446.00
|
| EBITDA |
-$20.03 M |
-$15.60 M |
-$14.27 M |
-$8.95 M |
-$7.39 M |
-$4.24 M |
-$3.82 M |
-$4.09 M |
-$2.23 M |
-$406,568.00 |
| EBITDA Ratio |
-18.61
|
-11.34
|
-9
|
-9.91
|
-7.33
|
-4.2
|
-3.09
|
-2.72
|
-2.35
|
-0.26
|
| Operating Income Ratio |
-18.63
|
-11.35
|
-9
|
-9.92
|
-7.34
|
-4.22
|
-3.11
|
-2.8
|
-2.53
|
-0.36
|
| Total Other Income/Expenses Net |
-$7,245.00
|
$170,998.00
|
$3,405.00
|
$19,802.00
|
$12,027.00
|
$11,773.00
|
$10,261.00
|
-$17,954.00
|
-$24,620.00
|
-$30,373.00
|
| Income Before Tax |
-$20.06 M
|
-$15.45 M
|
-$14.29 M
|
-$8.94 M
|
-$7.53 M
|
-$4.26 M
|
-$3.83 M
|
-$4.22 M
|
-$2.43 M
|
-$592,687.00
|
| Income Before Tax Ratio |
-18.63
|
-11.23
|
-9.01
|
-9.9
|
-7.48
|
-4.21
|
-3.1
|
-2.81
|
-2.56
|
-0.38
|
| Income Tax Expense |
$0.00
|
-$170,998.00
|
$18,522.00
|
-$18,530.00
|
$141,745.00
|
$11,773.00
|
$0.00
|
$28,603.00
|
$120,000.00
|
$33,673.00
|
| Net Income |
-$20.06 M
|
-$15.28 M
|
-$14.31 M
|
-$8.92 M
|
-$7.67 M
|
-$4.26 M
|
-$3.83 M
|
-$4.22 M
|
-$2.55 M
|
-$592,687.00
|
| Net Income Ratio |
-18.63
|
-11.11
|
-9.02
|
-9.88
|
-7.62
|
-4.21
|
-3.1
|
-2.81
|
-2.68
|
-0.38
|
| EPS |
-1.23 |
-1.81 |
-2.25 |
-5.58 |
-7.09 |
-5.2 |
-5.32 |
-6.67 |
-4.54 |
-1.17 |
| EPS Diluted |
-1.23 |
-1.81 |
-2.25 |
-5.58 |
-7.09 |
-5.2 |
-5.32 |
-6.67 |
-4.54 |
-1.17 |
| Weighted Average Shares Out |
$16.33 M
|
$8.44 M
|
$6.37 M
|
$1.60 M
|
$1.08 M
|
$817,568.00
|
$720,371.00
|
$633,544.00
|
$562,094.00
|
$505,431.00
|
| Weighted Average Shares Out Diluted |
$16.33 M
|
$8.44 M
|
$6.37 M
|
$1.60 M
|
$1.08 M
|
$817,568.00
|
$720,371.00
|
$633,544.00
|
$562,094.00
|
$505,431.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
